Adamczyk-Sowa, M, Sowa, P, Adamczyk, J et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2016
This study looked at whether melatonin (a natural hormone that helps regulate sleep) could help reduce fatigue in people with multiple sclerosis. The researchers measured certain markers in the blood related to oxidative stress (cellular damage) and found that melatonin supplementation for 90 days lowered these harmful markers in all MS patient groups studied.
Since chronic fatigue affects 80–90% of MS patients and overlaps with ME/CFS pathophysiology (oxidative stress, immune activation, inflammatory mechanisms), this study's identification of plasma lipid hydroperoxides as a potential fatigue biomarker and demonstration of melatonin's antioxidant effects could inform therapeutic approaches in both conditions. Understanding shared oxidative and inflammatory mechanisms in fatigue-associated neurological diseases may lead to novel biomarkers and treatments applicable across diagnostic boundaries.
This study does not directly demonstrate efficacy in ME/CFS patients or prove that melatonin causes fatigue improvement through the measured biochemical changes. The correlation between LHP reduction and fatigue score improvement is not clearly established in the data presented, and the study does not prove causality. Additionally, findings from MS populations may not generalize to ME/CFS without direct validation in ME/CFS cohorts.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →